EGFR and neoplasm: Analysis of cytoskeleton-associated genes including RHOA, MYO9A, MYO9B, PXN, VCL, VASP, ACTβ, MYH9, as well as a selection of proto-oncogenic and tumour-suppressive targets related to drug anti-metastasis, such as BRAF, CDK4, EGFR, KEAP1, KRAS, PIK3CA, PTEN, PTPRD, TP5380–84 revealed no significant changes in expression levels, except for PXN, VASP, and KEAP1 (Fig. 7H–K).